Reserve your spot today for this Live Webcast!

Jointly provided by     This activity is supported by independent educational grants from bluebird bio and BioMarin. Thursday, November 5, 2020 11:30 AM - 1:00 PM ET

Learn About

The principles of gene therapy in the treatment of rare diseases Latest clinical trial updates Financial implications of gene therapy and potential payment models for appropriate use

Expert Faculty Presenters

	John Petrich, RPh, MS Manager, Investigational Drug Service Cleveland Clinic		Edmund Pezalla, MD, MPH CEO Enlightenment Bioconsult, LLC
	Mari-Pat Pusey, MBA Senior Product Director OptumRx

Who Should Attend?

This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, registered nurses, and other managed health care professionals.

Statement of Need/Program Overview

Although gene therapy is a promising treatment option for a number of diseases (including inherited disorders, some types of cancer, and certain viral infections), the technique remains risky and is still under investigation to ensure safety and efficacy. Furthermore, research in this field is particularly challenging given the inherent nature of rare diseases and genetic disorders. Approximately 30 million individuals in the United States are living with a rare disease, which by definition have a prevalence of 200,000 or fewer cases in the United States. Genetic disorders and other rare diseases present unique challenges for health insurers in terms of requisite clinical intervention, disease management, and economic burden. The treatment landscape in US health care has already evolved significantly over the past several decades and appears to be on the precipice of its most groundbreaking innovation to date: gene therapy. This program is designed to address the educational needs for payers and managed care professionals regarding the solutions necessary to address the unique clinical and financial considerations surrounding gene therapies that will ensure quality care and appropriate patient access.

Educational Objectives

At the conclusion of this activity, participants should be able to demonstrate improved ability to: Explain the molecular and physiologic principles of gene therapy in the treatment of rare diseases Review outcomes measures for clinical trials in gene therapy and the pertinent clinical trial data for investigational treatments Evaluate the financial implications of gene therapy in terms of acquisition costs reconciled with the potential for improved outcomes and reduced health care service utilization Assess current and proposed payment models aligned with appropriate use for high-cost therapies

Agenda

Date and Time Thursday, November 5, 2020 11:30 AM - 1:00 PM ET

11:30 AM	Pre-Activity Learning Assessment and Opening Comments/Overview Mari-Pat Pusey, MBA
11:35 AM	Principles of Gene Therapy and Measurement of Clinical Outcomes John Petrich, RPh, MS
12:05 PM	Assessing the Curative Benefits of Gene Therapy in a Cost Conscious Environment Edmund Pezalla, MD, MPH
12:25 PM	Medical and Pharmacy Management Strategies for Optimal Gene Therapy Outcomes Mari-Pat Pusey, MBA
12:45 PM	Audience Q&A Session
12:55 PM	Key Takeaways and Closing Comments; Post-Activity Assessment and Evaluation
1:00 PM	Adjournment

Accreditation Information

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008162-9999-20-1074-L01-P Type of Activity: Application

Continuing Nursing Education The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Disclosure of Conflicts of Interest Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. Hardware/Software Requirements Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up. Fee Information There is no fee for this educational activity. If you have any questions, please call (215) 619-8812 or email info@impactedu.net.